Milestone and Royalty Payments. 3.1 Milestone Payments As consideration for the licenses and rights granted in this Agreement, Abboxx xxxll make milestone payments to RiboGene, by Product for human pharmaceutical use in the Field, for development of such Product by Abboxx, Xxboxx Xxxiliate or Abboxx xxxlicensee for such human pharmaceutical purposes, as follows:
Milestone and Royalty Payments. 9.1 Nucana agrees to make milestone payments to UC3 as set forth in Schedule 2. Each milestone payment is owed whether the milestone is achieved by Nucana, an Affiliate, Licensee or Assignee. Nucana shall inform UC3 within [***] of the event and the payment shall be made within [***] of the notice of each event being served to UC3. If the milestone is achieved by a Licensee or Assignee, Nucana shall inform UC3 within [***] of Nucana’s knowledge of the event and payment shall be made within [***] of notice of each event being served to UC3.
Milestone and Royalty Payments. Where applicable, the Client shall pay to BioFocus the success fees, milestone payments, royalties and other payments described in that Schedule of Work. Confidential to Diabesity Inc. and BioFocus Any such payments due under a Schedule of Work are payable to BioFocus by the Client within 30 days of such payment becoming due.
Milestone and Royalty Payments. (a) Clinical Trial Milestone Payment.
Milestone and Royalty Payments. As partial consideration for the rights granted to Egalet hereunder, Egalet shall make the following payments to Acura:
Milestone and Royalty Payments. All Milestone Payments and Royalty payments due under this Agreement shall be paid in cash within one hundred (120) days of the end of the calendar year in which the applicable Miletone Payment and/or Royalty payment is earned. Each Milestone Payment and/or Royalty payment shall be accompanied by a statement of the amount of gross sales of Product, the calculation of Net Sales, the number of units of Product sold during such calendar year, and the amount of Milestone Payments and/or Royalties due. For clarity, if both Milestone Payments and Royalty payments are due with respect to the same calendar year, only one such statement is due covering both the Milestone Payments and Royalty payments.
Milestone and Royalty Payments. The Parties hereby agree, as promptly as possible on and after the Effective Date, to negotiate in good faith and reach agreement on an amendment to this Agreement or a separate agreement to be executed by the Parties which shall include (a) the development milestone payments, tiered sales milestones and tiered royalties on Net Sales customary for such agreements and to be paid by DS under the License Agreement(s) for each Licensed Product that is Developed and Commercialized under this Agreement and/or a License Agreement, which milestone payments and royalties shall include the milestone and royalty payments described in Schedule 3 and shall conform in all material respects with the terms and conditions set forth in Schedule 3, and (b) such additional provisions relating to royalty reports, payment mechanisms and dates, audit rights, overdue payments, taxes, currency conversion rates and other provisions as are usual and customary for inclusion in provisions relating to milestones and royalties in collaboration and license agreements between companies in the pharmaceutical industry of comparable sizes to the respective Parties. For purposes of clarity, such additional provisions shall supplement and shall not materially expand, limit or change the provisions set forth on Schedule 3. The Parties shall negotiate such amendment to this Agreement or separate agreement in good faith and with sufficient diligence as is required to execute and deliver such amendment or separate agreement within * (*) days of the Effective Date. In the event the Parties fail to execute and deliver the amendment to this Agreement or separate agreement within such * (*) day period, the Parties shall (a) use reasonable efforts to complete such negotiations and to execute and deliver the amendment to this Agreement or separate agreement as soon as possible after such * (*) day period and (b) without limiting the generality of the foregoing, after the expiration of such * (*) day period, each produce a list of issues on which they have failed to reach agreement and submit its list to the JEC to be resolved as a Unanimous Decision in accordance with Section 2.1.5.
Milestone and Royalty Payments. Section 4.29 of the Company Disclosure Letter contains a complete and accurate list of (a) all milestone, development or similar payments, both scheduled and unscheduled, and (b) all royalty or similar payments (including applicable percentages), in each case, which remain outstanding as of the date hereof, and the applicable time or trigger event upon which each such payment will be made and the product candidates to which such payments relate.
Milestone and Royalty Payments. 6.1 The Licensee shall pay the Licensor the following sums:
Milestone and Royalty Payments. (a) Ventrus shall promptly notify Licensor after the occurrence of the first PoP for a bacteria, and within five (5) Business Days of such notice, pay Licensor One Hundred Thousand U.S. dollars ($100,000). Ventrus shall also promptly notify Licensor after the occurrence of the first PoP for a virus, and concurrently with such notice, pay Licensor One Hundred Thousand U.S. dollars ($100,000). It is understood and agreed that, in any event, payment of the milestones set forth in this Section 6.2(a) shall be due and payable not later than the date Ventrus initiates formulation studies for the first Ventrus Product or Ventrus Therapy.
